Evidence map›Paper›PMID 42710662›Full record

ArticleThe Journal of biological chemistry2026

LAMTOR5 drives glioblastoma progression via activation of the HOXC9/YTHDF2 positive feedback loop.

Hui Shi, Zihan Sun, Jiaqi Guo, Wencheng Feng, Jingjing Fu, Changying Wang, Yanjun Song, Yong Wang, Huabao Xiong, Runping Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hui ShiInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China; Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zihan SunState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine; Key Laboratory of Chemical Biology (Ministry of Education); Shandong Basic Science Research Center (Pharmacy); School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Jiaqi GuoInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China.
Wencheng FengState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine; Key Laboratory of Chemical Biology (Ministry of Education); Shandong Basic Science Research Center (Pharmacy); School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Jingjing FuInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China.
Changying WangInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China.
Yanjun SongState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine; Key Laboratory of Chemical Biology (Ministry of Education); Shandong Basic Science Research Center (Pharmacy); School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Yong WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Electronic address: doctorwy@163.com.
Huabao XiongInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, Shandong, China. Electronic address: xionghbl@163.com.
Runping FangCheeloo College of Medicine, Shandong University, Jinan, Shandong, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine; Key Laboratory of Chemical Biology (Ministry of Education); Shandong Basic Science Research Center (Pharmacy); School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China; Suzhou Research Institute of Shandong University, Suzhou, Jiangsu, China; Advanced Medical Research Institute/Translational Medicine Core Facility of Advanced Medical Research Institute, Shandong University, Jinan, Shandong, China. Electronic address: fangrunping@sdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults, characterized by high invasiveness and poor prognosis. The knowledge of driver genes and prognostic markers predictive of poor outcomes in GBM is still limited. In the current article, we show that late endosomal/lysosomal adapter and MAPK and MTOR activator 5 (LAMTOR5) is a driver gene for GBM progression through transcriptionally activating the HOXC9/YTHDF2 positive feedback loop. LAMTOR5 is highly expressed in GBM, predicts poor prognosis in glioma patients and is essential for the growth, invasion, and tumorigenesis of GBM cells. Using a bioinformatics analysis approach based on multiple public datasets, we identified YTHDF2 as a downstream effector of LAMTOR5. LAMTOR5 promotes the expression of YTHDF2 through increasing its promoter activity by coactivating the transcription factor HOXC9. In turn, the LAMTOR5-upregulated YTHDF2 enhances the expression of HOXC9 through promoting the mRNA stability of HOXC9 in an m

Indexed as

glioblastomaHOXC9LAMTOR5N(6)-methyladenosineYTHDF2

Identifiers

PMID42710662
PMCPMC13656544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.